Sedana Medical AB (SEDANA) AI Stock Analysis

• Market Cap: €1.61B
• Dividend Yield: N/A
• Average Volume (3M): 365.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.11
• Revenue Growth: 16.27%
• EPS Growth: -22.61%
• Country: SE
• Employees: 113
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Devices
• EPS (TTM): -0.13
• Shares Outstanding: 99,336,960
• 10 Day Avg. Volume: 302,919
• 30 Day Avg. Volume: 365,352
• PEG Ratio: 2.17
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 10.60
• P/FCF Ratio: -10.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €15.46
• Price Target Upside: -3.47% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: kr15.50 ▼(-3.25% Downside)

Sedana Medical AB's stock score is primarily influenced by its strong technical momentum, despite significant financial challenges and poor valuation metrics. The company's stable balance sheet offers some financial security, but profitability and cash flow issues need addressing to improve its overall financial health.

Sedana Medical AB Business Overview & Revenue Model

Company Description

Sedana Medical AB (SEDANA) is a Swedish medical technology company specializing in the development and commercialization of medical devices and pharmaceuticals for inhaled sedation. The company's flagship product, the AnaConDa, is an innovative device designed to facilitate the administration of volatile anesthetics for sedation in intensive care units. Sedana Medical operates in the healthcare sector, focusing on improving patient care and outcomes through advanced sedation solutions.

How the Company Makes Money

Sedana Medical makes money primarily through the sale of its AnaConDa device and related consumables. The company generates revenue by providing hospitals and healthcare facilities with its proprietary sedation systems, which are designed to reduce the need for intravenous sedatives and improve patient outcomes. Additionally, Sedana Medical may enter into strategic partnerships and collaborations with other healthcare organizations to enhance its market reach and product offerings. The company also invests in research and development to continually innovate and expand its product line, contributing to its long-term revenue growth.

Sedana Medical AB Financial Statement Overview

Summary

Sedana Medical shows strong revenue growth and a robust balance sheet with low leverage. However, persistent negative margins and cash flow challenges indicate ongoing operational inefficiencies, necessitating focus on profitability and cash flow improvement.

Income Statement

Sedana Medical's revenue has shown a steady increase over the years, with a notable revenue growth rate of 30.1% in the TTM (Trailing-Twelve-Months) compared to 2022. However, the company continues to experience negative profitability with a net profit margin of -29.2% and an EBIT margin of -25.3% in the TTM. These persistent losses indicate ongoing challenges in achieving operational efficiency and profitability.

Balance Sheet

The company maintains a strong equity position, with an equity ratio of 93.9% in the TTM, indicating financial stability. The debt-to-equity ratio is low at 0.005, reflecting minimal leverage and reduced financial risk. However, the ongoing operational losses impact return on equity, which remains negative.

Cash Flow

Free cash flow remains negative, though it improved slightly in the TTM with a growth rate of 17.7% compared to 2024. The operating cash flow to net income ratio is negative, indicating the company is not generating sufficient cash from operations to cover its net losses. This highlights a need for improved cash management and operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	196.12M	178.75M	153.87M	122.86M	159.15M	141.77M
Gross Profit	138.02M	126.14M	108.98M	86.07M	106.71M	88.90M
EBITDA	-18.92M	-4.03M	-51.67M	-64.87M	-49.10M	-17.22M
Net Income	-50.85M	-10.67M	-59.61M	-73.51M	-57.97M	-27.14M
Balance Sheet
Total Assets	978.89M	1.02B	1.01B	1.08B	1.17B	600.10M
Cash, Cash Equivalents and Short-Term Investments	130.71M	193.96M	381.80M	607.74M	836.18M	376.17M
Total Debt	4.87M	5.92M	4.31M	8.74M	8.87M	8.29M
Total Liabilities	58.66M	61.17M	44.06M	52.43M	66.12M	49.00M
Stockholders Equity	920.23M	958.23M	970.00M	1.03B	1.10B	551.09M
Cash Flow
Free Cash Flow	-130.77M	-186.77M	-206.95M	-253.22M	-151.48M	-92.47M
Operating Cash Flow	-28.48M	-11.77M	-38.06M	-115.43M	-41.22M	-7.85M
Investing Cash Flow	-127.15M	-44.67M	-321.96M	-137.78M	-110.25M	-84.62M
Financing Cash Flow	-3.91M	-3.57M	-4.86M	-1.51M	605.07M	5.79M

Sedana Medical AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 16.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SEDANA, the sentiment is Positive. The current price of 16.02 is below the 20-day moving average (MA) of 16.07, above the 50-day MA of 13.89, and above the 200-day MA of 13.93, indicating a neutral trend. The MACD of 0.56 indicates Positive momentum. The RSI at 54.61 is Neutral, neither overbought nor oversold. The STOCH value of 26.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SEDANA.

Sedana Medical AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SEDANA	54 Neutral	€1.61B	―	-5.40%	―	16.27%	-22.61%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
PXMBF	―	$180.10M	80.83	2.64%	―	―	―
SNZZF	―	$110.48M	―	-35.36%	―	―	―
24C	―	€100.47M	42.79	7.87%	―	―	―
6Y1	―	€81.02M	―	-19.18%	―	―	―
OSSD	58 Neutral	kr1.57B	―		―	36.23%	63.14%

Sedana Medical AB Corporate Events

Sedana Medical Reports Strong Q2 2025 Sales Growth Amid Currency Challenges

Sedana Medical AB reported a strong sales growth of 21% in Q2 2025, driven by increased sales and reduced operating costs, despite facing challenges from unrealized currency effects. The company continues its registration preparation work in the USA, impacting cash flow from investments in intangible assets, while maintaining a focus on improving cash flow from operations outside the US.

Sedana Medical’s Paediatric Study Published in The Lancet

Sedana Medical AB has announced the publication of its IsoCOMFORT paediatric study in The Lancet Respiratory Medicine, marking a significant achievement in paediatric critical care research. The study, which is the largest of its kind for inhaled isoflurane sedation, demonstrated the efficacy and safety of Sedaconda ACD in children aged 3-17, leading to paediatric approval in 13 European countries and extending market exclusivity until 2032. This development not only enhances Sedana Medical’s market position but also provides a significant clinical benefit over existing therapies, impacting stakeholders positively.

Sedana Medical to Present Q2 2025 Interim Report

Sedana Medical AB is set to release its interim report for the second quarter of 2025 on July 18, with a presentation scheduled for the same day. The report will be presented by the CEO, CFO, and CMO, providing insights into the company’s performance and strategy, which could impact its market positioning and stakeholder interests.

Sedana Medical’s US Studies Achieve Key Endpoint in Opioid Reduction

Sedana Medical AB announced that its pivotal US studies, INSPiRE-ICU 1 and 2, have successfully met a key secondary endpoint by demonstrating a significant reduction in opioid doses compared to the control group. This achievement supports the company’s aim for US registration of its Sedaconda ACD device and isoflurane for ICU sedation, potentially impacting the US market by providing an alternative to opioid use. The results, which align with previous European studies, will be crucial for the FDA’s assessment of Sedana Medical’s marketing authorization application.